| 2:55:05 PM - Fri, Nov 5th 2021 |
|
US FDA gives green light to encourage Modernna and J&J vaccines and supports cross-injection formulations
The U.S. Food and DrugSLOTXOAdministration (FDA) on Wednesday (Oct. 20) approved Moderna and Johnson & Johnson's new trigger needle vaccination against COVID-19, along with support for cross-formula vaccines. By saying that Americans can choose different types of vaccines. from the first injection be a stimulant
This decision gives millions of people in the United States additional protection from the new coronavirus delta mutation that has caused vaccination cases and continues to infect. (severe infection) in people who have been fully vaccinated
The U.S. Food and Drug Administration previously approved Pfizer Inc.'s syringe for COVID-19, a syringe developed with Germany's Bio-Tech SE, at least 6 months after the first two injections to increase vaccination. Protection for people aged 65 and over who are at risk of severe infections and those occupations that are at risk of infection
last week US Food and Drug Administration Advisory Board Three doses of Moderna vaccine are recommended for the same age.
In addition, the advisory panel of the US Food and Drug Administration Johnson & Johnson 2 vaccination is recommended for all recipients who receive their first dose for at least 2 months.
The U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention (CDC) are under pressure to approve the booster vaccine. After the White House announced plans for a broader booster vaccination program in August,
The advisory panel also presented data on cross-formula vaccines from the US National Institutes of Health, in which 458 volunteers were cross-vaccinated. Pfizer/Biontech Moderna and Johnson & Johnson
Data shows that people who have been vaccinated against COVID-19 Johnson & Johnson's first dose had a stronger immune response when stimulated by Pfizer or Moderna vaccines, and "cross-over" injections. safe in the adult population
Many countries including the United Kingdom Support a broad cross-formula vaccination strategy for the AstraZeneca vaccine. and although it is not yet approved in the US Rather, it was built on the basis of vector virus technology. Like Johnson & Johnson
|
